- 专利标题: Polypeptides modulating SIGLEC dependent immune responses
-
申请号: US17326709申请日: 2021-05-21
-
公开(公告)号: US11738069B2公开(公告)日: 2023-08-29
- 发明人: Christoph Kannicht , Stefan Winge , Guido Kohla , Barbara Solecka-Witulska
- 申请人: OCTAPHARMA AG
- 申请人地址: CH Lachen
- 专利权人: OCTAPHARMA AG
- 当前专利权人: OCTAPHARMA AG
- 当前专利权人地址: CH Lachen
- 代理机构: Wenderoth, Lind & Ponack, L.L.P.
- 优先权: EP 170690 2016.05.20
- 分案原申请号: US16302447
- 主分类号: A61K38/37
- IPC分类号: A61K38/37 ; C07K14/745 ; C07K14/755 ; A61P7/04 ; C12N15/62 ; A61K38/00
摘要:
The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.
公开/授权文献
信息查询
IPC分类: